Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Jun;36(6):935-8.
doi: 10.1136/gut.36.6.935.

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid

Affiliations
Clinical Trial

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid

R A Jorgensen et al. Gut. 1995 Jun.

Abstract

Ursodeoxycholic acid (UDCA) leads to biochemical and clinical improvement in many patients with primary biliary cirrhosis (PBC); although, the response is variable. This study compared UDCA treated patients with complete normalisation of biochemical functions to those without such improvement. Of the 65 patients receiving UDCA, 12 (19%) showed normalisation of liver biochemical functions at two years. The remaining 53 patients showed a less complete response. Mean (SD) alkaline phosphatase and total serum bilirubin values were significantly lower at entry in the patients whose liver biochemistry tests normalised (912 (732) U/l v 1417 (1021) U/l, p = 0.003, and 0.7 (12.1 (5.2) mumol/l v 38.9 (48.5) mumol/l, p = 0.0002, respectively), and percentage of UDCA in biliary bile acid was higher (56.3 (9.5)% v 38.3 (21.1)%, p = 0.03). Patients with biochemically and histologically less severe disease, and greater enrichment of biliary bile with UDCA, are more likely to respond favourably to the drug. The main objective of continued study will be to find out if normal liver biochemical functions can retard disease progression. The association of greater UDCA enrichment with complete biochemical responses suggests that higher doses of UDCA should be evaluated.

PubMed Disclaimer

References

    1. J Clin Invest. 1992 Feb;89(2):420-31 - PubMed
    1. Hepatology. 1992 Aug;16(2):358-64 - PubMed
    1. N Engl J Med. 1991 May 30;324(22):1548-54 - PubMed
    1. Hepatology. 1990 Sep;12(3 Pt 1):492-7 - PubMed
    1. Hepatology. 1990 Sep;12(3 Pt 1):486-91 - PubMed

Publication types